Page last updated: 2024-09-05

lapatinib and dasatinib

lapatinib has been researched along with dasatinib in 34 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(dasatinib)
Trials
(dasatinib)
Recent Studies (post-2010) (dasatinib)
1,9193051,4422,7072162,081

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)dasatinib (IC50)
Aurora kinase AHomo sapiens (human)2.633
Mitogen-activated protein kinase 13Homo sapiens (human)0.1
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.109
Bile salt export pumpHomo sapiens (human)10
Tyrosine-protein kinase ABL1Homo sapiens (human)0.9374
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.1922
Epidermal growth factor receptorHomo sapiens (human)0.7144
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.164
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.71
Tyrosine-protein kinase LckHomo sapiens (human)0.0015
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)0.0004
Tyrosine-protein kinase FynHomo sapiens (human)0.0012
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0078
Tyrosine-protein kinase YesHomo sapiens (human)0.0006
Tyrosine-protein kinase LynHomo sapiens (human)0.0012
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.2665
Tyrosine-protein kinase HCKHomo sapiens (human)0.001
Platelet-derived growth factor receptor betaHomo sapiens (human)0.028
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0276
Breakpoint cluster region proteinHomo sapiens (human)0.4946
Fibroblast growth factor receptor 1Homo sapiens (human)0.88
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0015
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0365
Tyrosine-protein kinase BlkMus musculus (house mouse)0.008
Ephrin type-A receptor 2Homo sapiens (human)0.0689
Ephrin type-B receptor 2Homo sapiens (human)0.0044
Vascular endothelial growth factor receptor 2Homo sapiens (human)2.36
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)1.7
Tyrosine-protein kinase CSKHomo sapiens (human)0.0013
Tyrosine-protein kinase TecHomo sapiens (human)0.297
Tyrosine-protein kinase TXKHomo sapiens (human)0.0003
Tyrosine-protein kinase SYKHomo sapiens (human)4.82
Casein kinase I isoform alphaHomo sapiens (human)0.001
LIM domain kinase 1Homo sapiens (human)0.6097
LIM domain kinase 2Homo sapiens (human)0.5186
Mitogen-activated protein kinase 12Homo sapiens (human)0.1
Ephrin type-B receptor 4Homo sapiens (human)0.001
Serine/threonine-protein kinase SIK1Homo sapiens (human)0.001
Myelin transcription factor 1Homo sapiens (human)0.063
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)1.7
Tyrosine-protein kinase BTKHomo sapiens (human)0.0036
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.0143
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)0.228
Protein-tyrosine kinase 6Homo sapiens (human)0.0071
Mitogen-activated protein kinase 11Homo sapiens (human)0.1
Mitogen-activated protein kinase 14Homo sapiens (human)0.1
Discoidin domain-containing receptor 2Homo sapiens (human)0.1127
Aurora kinase BHomo sapiens (human)6.485
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)0.104
Serine/threonine-protein kinase SIK2Homo sapiens (human)0.003
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2
Serine/threonine-protein kinase SIK3Homo sapiens (human)0.005

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (11.76)29.6817
2010's20 (58.82)24.3611
2020's10 (29.41)2.80

Authors

AuthorsStudies
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Morphy, R1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Chen, G; Chen, S; Chen, Y; Ding, J; Meng, L; Tong, L; Wang, J; Wang, X; Xie, Y; Yang, C1
Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H1
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR1
Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM1
Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM1
Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B1
Gelderblom, H; Guchelaar, HJ; van Erp, NP1
Clynes, M; McMahon, G; O'Connor, R; Roche, S1
Baergen, RN; Boeck, M; Christos, P; Chuang, E; Cigler, T; Cobham, MV; Donovan, D; Jain, S; Lam, C; Lane, ME; Mittal, V; Moore, A; O'Loughlin, J; Rafii, S; Schneider, S; Swistel, A; Vahdat, LT; Ward, MM; Wiener, N1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A1
Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W1
Mehra, R; Zibelman, M1
Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A1
Dekker, H; Labots, M; Meijer, GA; Pham, TV; Ruijter, R; Van der Hoeven, JJM; Van der Mijn, JC; Van der Vliet, HJ; Verheul, HMW1
Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D1
Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS1
Chen, CH; Chen, HF; Chen, JY; Hsu, YM; Huang, CH; Huang, WC; Huynh, TK; Liu, LC; Tu, CY; Wei, YL; Yang, YS; Yao, JH1
Feng, M; Li, Q; Liao, W; Qian, Z; Wen, F; Wu, Q; Yang, Y1
Tan, J; Xu, M; Zhong, Z1
Aure, MR; Engebraaten, O; Haugen, MH; Hongisto, V; Kristensen, VN; Leivonen, SK; Mælandsmo, GM; Normann, LS; Sahlberg, KK; Tahiri, A1

Reviews

8 review(s) available for lapatinib and dasatinib

ArticleYear
Selectively nonselective kinase inhibition: striking the right balance.
    Journal of medicinal chemistry, 2010, Feb-25, Volume: 53, Issue:4

    Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Humans; Protein Binding; Protein Kinase Inhibitors; Structure-Activity Relationship

2010
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
    Journal of medicinal chemistry, 2012, Jun-14, Volume: 55, Issue:11

    Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors

2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors

2021
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022
Clinical pharmacokinetics of tyrosine kinase inhibitors.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution

2009
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    American journal of clinical oncology, 2016, Volume: 39, Issue:4

    Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus

2016
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
    Bulletin du cancer, 2016, Volume: 103, Issue:5

    Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk

2016

Trials

1 trial(s) available for lapatinib and dasatinib

ArticleYear
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
    Breast cancer research and treatment, 2012, Volume: 132, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Count; Cohort Studies; Dasatinib; Female; Hemangioblasts; Hematopoietic Stem Cells; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Thiazoles; Trastuzumab; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2012

Other Studies

25 other study(ies) available for lapatinib and dasatinib

ArticleYear
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
    Bioorganic & medicinal chemistry letters, 2012, Jan-01, Volume: 22, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Furans; Humans; Inhibitory Concentration 50; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines

2012
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
    European journal of medicinal chemistry, 2013, Volume: 61

    Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship

2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Journal of medicinal chemistry, 2014, Oct-09, Volume: 57, Issue:19

    Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship

2014
Highly predictive and interpretable models for PAMPA permeability.
    Bioorganic & medicinal chemistry, 2017, 02-01, Volume: 25, Issue:3

    Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine

2017
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
    Bioorganic & medicinal chemistry, 2019, 07-15, Volume: 27, Issue:14

    Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility

2019
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
    Bioorganic & medicinal chemistry, 2020, 09-15, Volume: 28, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles

2020
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
    Scientific reports, 2020, 11-26, Volume: 10, Issue:1

    Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States

2020
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jul-15, Volume: 877, Issue:22

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2009
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Dec-01, Volume: 877, Issue:31

    Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dasatinib; Humans; Lapatinib; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sensitivity and Specificity; Thiazoles

2009
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
    British journal of pharmacology, 2014, Volume: 171, Issue:24

    Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles

2014
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
    The oncologist, 2018, Volume: 23, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2018
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
    Oncology reports, 2020, Volume: 43, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome

2020
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
    Breast cancer research : BCR, 2020, 08-08, Volume: 22, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Lapatinib; Mice; Mice, Nude; Oncogene Proteins, Fusion; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Tamoxifen; Xenograft Model Antitumor Assays

2020
miR-221 confers lapatinib resistance by negatively regulating p27
    Cancer science, 2021, Volume: 112, Issue:10

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O3; Hepatocyte Nuclear Factor 3-gamma; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Microarray Analysis; MicroRNAs; NF-kappa B p50 Subunit; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; src-Family Kinases; Up-Regulation

2021
Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.
    BMC bioinformatics, 2022, Oct-19, Volume: 23, Issue:1

    Topics: Adenosine; Afatinib; Crizotinib; Dasatinib; Drug Resistance; Erlotinib Hydrochloride; Etoposide; Humans; Lapatinib; Lung Neoplasms; Tumor Microenvironment; Ubiquitin-Protein Ligases

2022
Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
    Pathology oncology research : POR, 2022, Volume: 28

    Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Liver Neoplasms; Oxidative Stress; Prognosis; RNA, Long Noncoding; Sorafenib

2022
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.
    PloS one, 2023, Volume: 18, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dasatinib; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab

2023